Discovering a new drug is one of the most difficult and expensive challenges in science.

It often takes more than a decade and billions of dollars to bring a medicine to market. Even then, most drug candidates fail long before reaching patients.

For decades the process has relied largely on trial and error. Scientists test ideas in the lab, study the results, adjust their approach, and try again. It can take years just to determine whether a potential drug target is even worth pursuing.

Artificial intelligence is beginning to change that.

Instead of relying entirely on laboratory experimentation, researchers can now analyze massive biological datasets first. AI systems can help narrow down the most promising targets and molecular designs before scientists even begin testing in the lab.

One company working at this intersection is MindWalk.

MindWalk is a biotechnology company focused on using artificial intelligence to help researchers discover new medicines faster and more efficiently.

The company is still relatively small compared with major pharmaceutical firms, but the platform it is building offers a glimpse into how drug discovery may evolve over the coming decade.

Every drug discovery program begins with a simple but difficult question:

What exactly in the body should we target to treat a disease?

Finding that target is surprisingly complex.

Scientists must analyze thousands of research papers, biological datasets, and experimental results to identify which proteins or biological pathways might be responsible for a disease.

Even when researchers identify a promising target, designing a molecule that interacts with it in the right way is another major challenge.

The process can take years of laboratory work before a viable drug candidate even begins clinical testing.

Artificial intelligence may help compress that timeline.

By analyzing biological data at scale, AI platforms can help researchers narrow the search space dramatically, allowing scientists to focus their laboratory work on the most promising possibilities.

Drug discovery produces enormous amounts of biological data.

Artificial intelligence is particularly well suited to identifying patterns within large and complex datasets, making it a natural fit for pharmaceutical research.

Because of this, many pharmaceutical companies are beginning to integrate machine learning into their discovery pipelines.

Industry estimates suggest the AI drug discovery market could grow from roughly US$6.9 billion in 2025 to around US$17.8 billion over the next decade.

At the same time, the broader life sciences analytics market could approach US$70 billion by 2030.

Platforms that combine biological data, machine learning, and experimental validation may increasingly become central tools in the pharmaceutical industry.

MindWalk’s research touches several areas of medicine where demand for new treatments remains strong.

Cancer

The company is involved in antibody-based approaches to cancer, an area where researchers are developing increasingly targeted therapies.

Metabolic Disease

MindWalk is also exploring AI-driven approaches related to GLP-1 therapies, the class of drugs that has recently transformed treatment for obesity and diabetes.

Infectious Disease

Researchers at the company have identified a shared viral target across multiple dengue virus strains, which could potentially support future vaccine development.

MindWalk is still in the early stages of building its platform, but the company has begun to show encouraging momentum.

Revenue has grown from approximately US$13.7 million in 2020 to roughly US$17.6 million more recently, supported largely by research collaborations and discovery programs.

More recently, growth has accelerated.

In the first half of fiscal 2025, revenue increased more than 40 percent year over year, driven largely by growth in research projects.

Margins have also improved, with gross margins rising to roughly 58 percent, compared with about 46 percent the previous year.

Like many companies working at the intersection of AI and biotechnology, MindWalk continues to invest heavily in research and platform development as it expands its capabilities.

The company recently made a significant strategic move.

MindWalk sold its European operations to focus the business more directly around its artificial intelligence discovery platform.

Previously operating under the name ImmunoPrecise Antibodies, the company historically performed a large amount of contract research work for pharmaceutical companies.

By divesting its European operations, management streamlined the organization and redirected resources toward its AI technologies and discovery capabilities.

Following the transaction, the company reported approximately US$16.5 million in cash, strengthening its balance sheet as it continues developing the platform.

One reason MindWalk’s platform is particularly interesting is the company’s historical foundation in laboratory biology.

Long before shifting toward artificial intelligence, the company spent decades performing antibody discovery and research for pharmaceutical partners.

Over time this work produced extensive proprietary datasets and thousands of antibody records generated through real laboratory experiments.

These datasets now provide an important foundation for the company’s AI systems.

Rather than relying purely on theoretical biological data, the platform is informed by years of experimental work, helping connect computational predictions with real biological validation.

Looking ahead, MindWalk appears focused on expanding the ecosystem around its LensAI platform.

In addition to research collaborations, the company is developing additional revenue streams such as:

The goal is to build datasets, algorithms, and intellectual property that can support multiple discovery programs simultaneously.

MindWalk has already formed collaborations with several biotechnology companies, including OmniAb, BriaCell Therapeutics, and Xyphos Biosciences.

These partnerships allow the company to apply its technology to real discovery programs while expanding its presence within the biotechnology industry.

The easiest way to understand MindWalk’s platform is through two simple ideas.

HYFT is the brain.

LensAI is the interface.

HYFT is the discovery engine running behind the scenes.

It analyzes large amounts of biological data and generates potential drug candidates that could interact with disease targets.

LensAI is the platform researchers use to interact with that system.

It organizes scientific research, biological datasets, and experimental results into a structured environment scientists can explore and analyze.

A simple way to picture the process is this:

LensAI finds the lock.

HYFT designs the keys.

LensAI helps researchers identify which biological “lock” in the body might be responsible for a disease.

HYFT then generates possible molecular “keys” that could interact with that target.

Those keys may look structurally different, but they can still produce the same biological function, an idea that sits at the core of the platform’s discovery approach.

Together, the two systems help researchers move from identifying a disease target to designing molecules that might treat it.

MindWalk also supports this work with laboratory capabilities that allow discoveries generated by the platform to be tested experimentally, creating a powerful feedback loop between AI predictions and real biological validation.

Historically, much of MindWalk’s revenue has come from discovery partnerships and research collaborations with pharmaceutical companies.

But the company is increasingly applying its platform to develop its own therapeutic programs.

Using its AI systems, researchers can identify promising disease targets and design molecules that may interact with them. These discoveries can then be tested experimentally using the company’s laboratory infrastructure.

Several internal programs are now being explored, including work in infectious disease and vaccine development.

If successful, internally developed drug candidates could represent a much larger long-term opportunity than discovery services alone.

Artificial intelligence is becoming an increasingly important tool in pharmaceutical research.

Companies that can combine large biological datasets, advanced AI models, and laboratory validation may play a growing role in how new medicines are discovered.

MindWalk’s platform brings these elements together.

By pairing HYFT, the discovery engine generating potential drug candidates, with LensAI, the platform researchers use to explore biological data, the company is working to help scientists move more efficiently from identifying disease targets to designing potential treatments.

If platforms like this succeed, they could help shift drug discovery from a slow trial-and-error process toward a more predictive, data-driven model.

And if that shift happens, the way new medicines are discovered in the coming decades may look very different from the way it works today.